Speaker Spotlight: Ricardo Grieshaber-Bouyer
Professor of Clinical Systems Immunology, FAU Erlangen Nürnberg
Head of the Clinical Trial Unit, University Hospital Erlangen
We are delighted to highlight Prof. Dr. med. Ricardo Grieshaber-Bouyer, a trailblazing physician scientist shaping the future of autoimmune disease treatment through pioneering work in systems immunology, precision cell depletion, and next-generation immune modulating therapies.
Leading the Next Era of Clinical Systems Immunology
Prof. Grieshaber-Bouyer leads a dynamic research program at the Department of Internal Medicine 3 – Rheumatology and Immunology, at the University Hospital Erlangen. His lab investigates how immune cell heterogeneity drives inflammation, chronic disease, and individual patient variation, using high dimensional patient profiling, CRISPR based perturbation systems, and translational models.
Breakthrough Clinical Innovation
Prof. Grieshaber-Bouyer is internationally recognized for translating breakthrough immunology into first-in-patient therapies. His team has led some of the world’s earliest clinical applications of T cell redirecting therapies, including T cell engagers and CAR T cells for severe autoimmune diseases. These landmark studies have been published in Nature Medicine and the New England Journal of Medicine, setting new clinical benchmarks for curative treatment strategies.
He also serves as a Global Principal Investigator for innovative early phase trials, overseeing a portfolio of cutting edge studies focused on precision cell depletion and immune reset.
Bridging Academia & Industry
Alongside his academic leadership, Prof. Grieshaber‑Bouyer brings strategic insight across the biotech ecosystem. He actively collaborates with industry as a Scientific Advisory Board member and consultant, guiding preclinical benchmarking, asset evaluation, and clinical development strategies. His impact has been recognized globally, most notably through his inclusion in the Forbes 30 Under 30 Europe list for Science & Healthcare (2025).
Transformative Discoveries in Autoimmune Disease
Most recently, Prof. Grieshaber-Bouyer led a breakthrough clinical trial that revealed how deeply disease driving plasma cells anchor severe autoimmune conditions. He also demonstrated that T cell engager therapy can “release the anchor,” resulting in rapid and profound clinical improvement for patients who had not responded to conventional treatments.
This work is accelerating a major shift toward curative immune resetting. It aligns directly with the cutting edge conversations taking place at our summit.
At the Immune Resetting Summit
At this year’s Immune Resetting: B-Cell Mediated & Beyond Summit, Prof. Grieshaber-Bouyer will share critical insights spanning:
- The evolving landscape of T-cell engagers in autoimmunity
- Designing human-relevant preclinical models that reflect real autoimmune biology
- Comparing TCEs vs. cell therapy to guide smarter modality selection
- Translational lessons derived from early phase clinical trials
View his profile here.
Why You Won’t Want to Miss This
Prof. Grieshaber-Bouyer stands at the forefront of a rapidly emerging therapeutic frontier. His blend of scientific precision, clinical leadership, and translational impact makes him one of the most compelling voices to lead discussions on immune resetting, autoimmune cure pathways, and next generation engineering of the immune system.